Dec 14, 2015 7:05am EST Matinas BioPharma’s Lead Antibacterial Development Candidate MAT2501 Granted QIDP Designation by U.S. FDA
Nov 19, 2015 7:05am EST Matinas BioPharma to Present at the 8th Annual LD Micro Main Event on December 3, 2015
Nov 10, 2015 7:35am EST Matinas BioPharma Reports 2015 Third Quarter Financial Results and Provides Business Update
Oct 26, 2015 8:05am EDT Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Encochleated siRNA
Oct 22, 2015 8:05am EDT Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
Oct 14, 2015 7:05am EDT Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015
Oct 10, 2015 8:00am EDT Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
Oct 05, 2015 7:00am EDT Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 – An Orally Delivered, Encochleated Formulation of Amphotericin B –
Sep 19, 2015 2:00pm EDT Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
Sep 18, 2015 3:00pm EDT Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
